Oncology | Preclinical Developments | GERMANY

Tubulis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Lead Product(s): TUB-010

Therapeutic Area: Oncology Product Name: TUB-010

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: BioMedPartners

Deal Size: $12.5 million Upfront Cash: Undisclosed

Deal Type: Series A Financing July 21, 2020

Details:

The funds will be used to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company.

GEMoaB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy

Lead Product(s): RevCAR-T 1

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Intellia Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 20, 2020

Details:

The companies will conduct joint research to combine GEMoaB’s proprietary RevCAR technology platform with Intellia’s proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies to treat cancers and inflammatory diseases.

Immatics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

GSK pays $50M for 2 solid tumor cell therapies from Immatics

Lead Product(s): Allogeneic T-cell therapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: $600.0 million Upfront Cash: $50.0 million

Deal Type: Collaboration February 20, 2020

Details:

GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science

Lead Product(s): BNT211

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 02, 2020

Details:

The data for BNT211 reports Claudin 6 as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a new RNA vaccine promoting the amplification of CAR-T cells in vivo.

Find

Find Novel Oncology Drugs in Preclinical Development in GERMANY

Germany

Product Type

Companies

Tubulis

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

GEMoaB

GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy

Immatics

GSK pays $50M for 2 solid tumor cell therapies from Immatics

BioNTech SE

BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science